*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter - as a primary diagnosis code | T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter - as a primary or secondary diagnosis code | |
|---|---|---|
| OUTCOMES | ||
| Avg. LOS | 5.9 | |
| Readmission Rate (%) | 26.64 | |
| Unplanned Readmission Rate (%) | 18.11 | |
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) | ||
| PAYMENTS AND CHARGES | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| MARKET SIZING & INCIDENCE RATES | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Yes) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Yes) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations after Exclusion | ||
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 918: POISONING AND TOXIC EFFECTS OF DRUGS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 917: POISONING AND TOXIC EFFECTS OF DRUGS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|
| Total Hospitalizations at DRG | 71,748 | |
| Total Hospitalizations with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 291 | |
| DRG Share of Total Hospitalizations | 0.22 | |
| % of Total ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter in DRG | 58.32 | |
| Avg LOS at DRG | 2.93 | |
| Avg LOS with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 3.42 | |
| Readmission Rate at DRG | 33.86 | |
| Readmission Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 19.35 | |
| Unplanned Readmission Rate at DRG | 10.34 | |
| Unplanned Readmission Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 14.7 | |
| Total Medicare payments at DRG | $313,351,773 | |
| Total Medicare payments with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $1,420,220 | |
| Total Medicare payment per Day at DRG | $1,489 | |
| Total Medicare payment per Day with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $1,429 | |
| Total Medicare payment per Hospitalization at DRG | $4,367 | |
| Total Medicare payment per Hospitalization with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $4,880 | |
| Total Medicare Charges at DRG | $1,750,048,705 | |
| Total Medicare Charges with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $8,808,702 | |
| Avg Charges at DRG | $24,392 | |
| Avg Charges with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $30,270 | |
| Mortality Rate at DRG | 0.22 | |
| Mortality Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | NA | |
| SNF Discharge Rate at DRG | 7.61 | |
| SNF Discharge Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 18.56 | |
| Home Discharge Rate at DRG | 51.88 | |
| Home Discharge Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 48.8 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 309: CARDIAC ARRHYTHMIA AND CONDUCTION DISORDERS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 683: RENAL FAILURE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 291: HEART FAILURE AND SHOCK WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 308: CARDIAC ARRHYTHMIA AND CONDUCTION DISORDERS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 682: RENAL FAILURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 292,335 | ||||
| Total Hospitalizations with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 1,610 | ||||
| DRG Share of Total Hospitalizations | 0.89 | ||||
| % of Total ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter in DRG | 8.38 | ||||
| Avg LOS at DRG | 2.96 | ||||
| Avg LOS with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 3.6 | ||||
| Readmission Rate at DRG | 19.18 | ||||
| Readmission Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 23.92 | ||||
| Unplanned Readmission Rate at DRG | 13.96 | ||||
| Unplanned Readmission Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 17.43 | ||||
| Total Medicare payments at DRG | $1,347,436,356 | ||||
| Total Medicare payments with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $8,182,970 | ||||
| Total Medicare payment per Day at DRG | $1,557 | ||||
| Total Medicare payment per Day with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $1,411 | ||||
| Total Medicare payment per Hospitalization at DRG | $4,609 | ||||
| Total Medicare payment per Hospitalization with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $5,083 | ||||
| Total Medicare Charges at DRG | $7,385,462,160 | ||||
| Total Medicare Charges with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $55,705,887 | ||||
| Avg Charges at DRG | $25,264 | ||||
| Avg Charges with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $34,600 | ||||
| Mortality Rate at DRG | 0.57 | ||||
| Mortality Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 0.75 | ||||
| SNF Discharge Rate at DRG | 11.55 | ||||
| SNF Discharge Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 20.56 | ||||
| Home Discharge Rate at DRG | 63.79 | ||||
| Home Discharge Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 43.23 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 292: HEART FAILURE AND SHOCK WITH COMPLICATION OR COMORBIDITY (CC) | DRG 310: CARDIAC ARRHYTHMIA AND CONDUCTION DISORDERS WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 392: ESOPHAGITIS, GASTROENTERITIS AND MISCELLANEOUS DIGESTIVE DISORDERS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 641: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 1,808,415 | ||||
| Total Hospitalizations with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 1,095 | ||||
| DRG Share of Total Hospitalizations | 5.5 | ||||
| % of Total ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter in DRG | 5.7 | ||||
| Avg LOS at DRG | 6.34 | ||||
| Avg LOS with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 7.08 | ||||
| Readmission Rate at DRG | 24.2 | ||||
| Readmission Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 23.79 | ||||
| Unplanned Readmission Rate at DRG | 16.78 | ||||
| Unplanned Readmission Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 16.02 | ||||
| Total Medicare payments at DRG | $21,288,214,047 | ||||
| Total Medicare payments with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $13,430,177 | ||||
| Total Medicare payment per Day at DRG | $1,857 | ||||
| Total Medicare payment per Day with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $1,731 | ||||
| Total Medicare payment per Hospitalization at DRG | $11,772 | ||||
| Total Medicare payment per Hospitalization with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $12,265 | ||||
| Total Medicare Charges at DRG | $107,155,481,388 | ||||
| Total Medicare Charges with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $83,139,776 | ||||
| Avg Charges at DRG | $59,254 | ||||
| Avg Charges with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $75,927 | ||||
| Mortality Rate at DRG | 12.11 | ||||
| Mortality Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 20.91 | ||||
| SNF Discharge Rate at DRG | 27.18 | ||||
| SNF Discharge Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 31.14 | ||||
| Home Discharge Rate at DRG | 25.81 | ||||
| Home Discharge Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 11.51 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 918: POISONING AND TOXIC EFFECTS OF DRUGS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 312: SYNCOPE AND COLLAPSE | DRG 917: POISONING AND TOXIC EFFECTS OF DRUGS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 948: SIGNS AND SYMPTOMS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 189: PULMONARY EDEMA AND RESPIRATORY FAILURE | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 71,748 | ||||
| Total Hospitalizations with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 350 | ||||
| DRG Share of Total Hospitalizations | 0.22 | ||||
| % of Total ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter in DRG | 1.82 | ||||
| Avg LOS at DRG | 2.93 | ||||
| Avg LOS with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 3.54 | ||||
| Readmission Rate at DRG | 33.86 | ||||
| Readmission Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 20.0 | ||||
| Unplanned Readmission Rate at DRG | 10.34 | ||||
| Unplanned Readmission Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 14.93 | ||||
| Total Medicare payments at DRG | $313,351,773 | ||||
| Total Medicare payments with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $1,807,960 | ||||
| Total Medicare payment per Day at DRG | $1,489 | ||||
| Total Medicare payment per Day with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $1,459 | ||||
| Total Medicare payment per Hospitalization at DRG | $4,367 | ||||
| Total Medicare payment per Hospitalization with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $5,166 | ||||
| Total Medicare Charges at DRG | $1,750,048,705 | ||||
| Total Medicare Charges with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $11,533,523 | ||||
| Avg Charges at DRG | $24,392 | ||||
| Avg Charges with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $32,953 | ||||
| Mortality Rate at DRG | 0.22 | ||||
| Mortality Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 7.61 | ||||
| SNF Discharge Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 19.14 | ||||
| Home Discharge Rate at DRG | 51.88 | ||||
| Home Discharge Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 47.71 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 280: ACUTE MYOCARDIAL INFARCTION, DISCHARGED ALIVE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 690: KIDNEY AND URINARY TRACT INFECTIONS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 640: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 193: SIMPLE PNEUMONIA AND PLEURISY WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 242: PERMANENT CARDIAC PACEMAKER IMPLANT WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 250,159 | ||||
| Total Hospitalizations with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 240 | ||||
| DRG Share of Total Hospitalizations | 0.76 | ||||
| % of Total ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter in DRG | 1.25 | ||||
| Avg LOS at DRG | 5.47 | ||||
| Avg LOS with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 7.2 | ||||
| Readmission Rate at DRG | 27.88 | ||||
| Readmission Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 30.57 | ||||
| Unplanned Readmission Rate at DRG | 19.94 | ||||
| Unplanned Readmission Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 23.58 | ||||
| Total Medicare payments at DRG | $2,661,443,545 | ||||
| Total Medicare payments with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $2,768,282 | ||||
| Total Medicare payment per Day at DRG | $1,946 | ||||
| Total Medicare payment per Day with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $1,602 | ||||
| Total Medicare payment per Hospitalization at DRG | $10,639 | ||||
| Total Medicare payment per Hospitalization with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $11,535 | ||||
| Total Medicare Charges at DRG | $13,270,497,724 | ||||
| Total Medicare Charges with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $16,961,273 | ||||
| Avg Charges at DRG | $53,048 | ||||
| Avg Charges with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | $70,672 | ||||
| Mortality Rate at DRG | NA | ||||
| Mortality Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 21.63 | ||||
| SNF Discharge Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 32.92 | ||||
| Home Discharge Rate at DRG | 34.87 | ||||
| Home Discharge Rate with ICD T460X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter | 25.83 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| BAY MEDICAL SACRED HEART | 615 N BONITA AVE | PANAMA CITY | FL | 32401 | 62 |
| JACKSON-MADISON COUNTY GENERAL HOSPITAL | 620 SKYLINE DR | JACKSON | TN | 38301 | 48 |
| MORRISTOWN MEDICAL CENTER | 100 MADISON AVE | MORRISTOWN | NJ | 07960 | 48 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. NIMESH K VESUWALA | 82 TUNNEL RD | POTTSVILLE | PA | 17901 | 13 |
| Dr. ANDREA LEA SMITH | 785 OHIO AVENUE | CLARKSDALE | MS | 38614 | 12 |
| Dr. MARIO ALBERTO PULIDO | 2624 ATLANTIC BLVD | JACKSONVILLE | FL | 32207 | 11 |